– CANADA, Richmond Hill – Helix BioPharma Corp. (TSX:HBP | FSE:HBP), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the resignation of Dr. Marek Orlowski as a director of the Company. In his place, the Board announced the appointment of Artur Gabor to the Board. Mr. Gabor has extensive experience in merger and acquisitions, corporate finance and restructuring.
“On behalf of the Board and management of Helix, I would like to thank Marek for his time and dedication, and wish him well in his future endeavors,” said Slawomir Majewski, Chairman of Helix. “In addition, we are extremely pleased in welcoming Mr. Gabor to Helix’s Board.”
About Helix BioPharma Corp.
Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix’s product development initiatives include its novel L-DOS47 new drug candidate and Chimeric Antigen Receptor based cell therapies. Helix is currently listed on the TSX and FSE under the symbol “HBP”.
For more information : http://www.helixbiopharma.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.